2-甲氧基-5,6-二甲基吡啶-3-胺 | 201676-71-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-甲氧基-5,6-二甲基吡啶-3-胺
• 英文名称: 5,6-dimethyl-2-methoxy-3-amino-pyridine
• 英文别名: 3-amino-5,6-dimethyl-2-methoxypyridine；2-methoxy-5,6-dimethylpyridin-3-amine
• CAS: 201676-71-3
• 化学式: C₈H₁₂N₂O
• 分子量: 152.196
• InChiKey: WFJKJTFISIHGIA-UHFFFAOYSA-N

物化性质

• 沸点：
  274.1±35.0 °C(Predicted)
• 密度：
  1.075±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  48.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-甲氧基-5,6-二甲基吡啶-3-胺 在 盐酸 、 正丁基锂 、 四甲基乙二胺 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 5.0h， 生成 3-amino-4-[(3,5-dimethylphenyl)methyl]-5,6-dimethyl-1H-pyridin-2-one
  参考文献：
  名称：

  4-Benzyl and 4-Benzoyl-3-dimethylaminopyridin-2(1H)-ones:  In Vitro Evaluation of New C-3-Amino-Substituted and C-5,6-Alkyl-Substituted Analogues against Clinically Important HIV Mutant Strains

  摘要：

  In a program to optimize the anti-HIV activity of the 4-benzyl and 4-benzoyl-3-dimethylaminopyridinones 9 and 10, lead compounds in a new class of highly potent non-nucleoside type inhibitors of HIV-1 reverse transcriptase, modification of the alkyl substitutents at the C-5 and C-6 positions on the pyridinone ring and of the substitutents on the C-3 amino group has been studied. Of the 17 new 5/6-modified analogues prepared, compounds 31b and 32b substituted at C-5 by an extended nonpolar chain containing an ether function and a C-6 methyl group and compound 35 bearing a C-5 ethyl/C-6 hydroxymethyl substituent pattern were selected on the basis of their in vitro activity against wild-type HIV and the three principle mutant strains, K103N, Y181C, and Y188L. When tested further, it was shown that these molecules, and in particular compound 35, are globally more active than 9, 10, and efavirenz against an additional eight single [L100I, K101E, V106A, E138K, V179E, G190A/S, and F227C] and four double HIV mutant strains [L1001 + K103N, K101E + K103N, K103N + Y181C, and F227L + V106A] which are clinically relevant. Concerning modulation of the N-3 substituent, 36 new analogues were prepared. Of these, the N-methyl-N-(2-methoxyethyl)-substituted compounds 40, 42, and 62, as well as the doubly modified compounds 77a and 77b, were selected from the initial screen and were subsequently shown to be active at sub-micromolar concentrations (IC50'S) against all the other mutant strains except K103N + Y181C and F227L + V106A. Two possible, but distinct, modes of binding of these analogues in RT were suggested from molecular modeling studies. The preferred mode of binding for compound 62, corresponding to the predicted "orientation 1", was revealed in the X-ray crystal structure of the compound 62-RT complex.

  DOI：

  10.1021/jm0408621
• 作为产物：
  描述：

  5,6-二甲基-1H-吡啶-2-酮 在 镍 硫酸 、 苄基三乙基氯化铵 、 氢气 、 硝酸 、 三氯氧磷 作用下， 以 四氢呋喃 、 甲醇 、 乙腈 为溶剂， 5.0~80.0 ℃ 、202.65 kPa 条件下， 反应 18.0h， 生成 2-甲氧基-5,6-二甲基吡啶-3-胺
  参考文献：
  名称：

  4-Benzyl and 4-Benzoyl-3-dimethylaminopyridin-2(1H)-ones:  In Vitro Evaluation of New C-3-Amino-Substituted and C-5,6-Alkyl-Substituted Analogues against Clinically Important HIV Mutant Strains

  摘要：

  In a program to optimize the anti-HIV activity of the 4-benzyl and 4-benzoyl-3-dimethylaminopyridinones 9 and 10, lead compounds in a new class of highly potent non-nucleoside type inhibitors of HIV-1 reverse transcriptase, modification of the alkyl substitutents at the C-5 and C-6 positions on the pyridinone ring and of the substitutents on the C-3 amino group has been studied. Of the 17 new 5/6-modified analogues prepared, compounds 31b and 32b substituted at C-5 by an extended nonpolar chain containing an ether function and a C-6 methyl group and compound 35 bearing a C-5 ethyl/C-6 hydroxymethyl substituent pattern were selected on the basis of their in vitro activity against wild-type HIV and the three principle mutant strains, K103N, Y181C, and Y188L. When tested further, it was shown that these molecules, and in particular compound 35, are globally more active than 9, 10, and efavirenz against an additional eight single [L100I, K101E, V106A, E138K, V179E, G190A/S, and F227C] and four double HIV mutant strains [L1001 + K103N, K101E + K103N, K103N + Y181C, and F227L + V106A] which are clinically relevant. Concerning modulation of the N-3 substituent, 36 new analogues were prepared. Of these, the N-methyl-N-(2-methoxyethyl)-substituted compounds 40, 42, and 62, as well as the doubly modified compounds 77a and 77b, were selected from the initial screen and were subsequently shown to be active at sub-micromolar concentrations (IC50'S) against all the other mutant strains except K103N + Y181C and F227L + V106A. Two possible, but distinct, modes of binding of these analogues in RT were suggested from molecular modeling studies. The preferred mode of binding for compound 62, corresponding to the predicted "orientation 1", was revealed in the X-ray crystal structure of the compound 62-RT complex.

  DOI：

  10.1021/jm0408621

文献信息

• Piperazine derivatives and process for the preparation thereof
  申请人：Samjin Pharmaceutical Co., Ltd.

  公开号：US06028195A1

  公开（公告）日：2000-02-22

  The present invention relates to novel compound having strong antimumor activities of the general formula(I) ##STR1## wherein R.sub.1 and R.sub.2 are independently hydrogen, substituted or unsubstituted C.sub.1 -C.sub.8 alkyl, substituted or unsubstituted C.sub.3 -C.sub.6 cycloalkyl, substituted or unsubstituted C.sub.2 -C.sub.8 unsaturated alkyl, ketone, substituted or unsubstituted aryl, substituted or unsubstituted C.sub.1 -C.sub.4 alkoxy, substituted or unsubstituted arylhydroxy, substituted or unsubstituted amino, C.sub.1 -C.sub.4 lower ester, C.sub.1 -C.sub.4 lower thioester, thiol, substituted or unsubstituted carboxyl, epoxy, substituted or unsubstituted C.sub.1 -C.sub.4 lower thioalkoxy; or R.sub.1 and R.sub.2 are fused to form C.sub.3 -C.sub.4 saturated or unsaturated chain; R.sub.3, R.sub.4, R.sub.5, R.sub.6 and R.sub.7 are independently hydrogen, halogen, hydroxy, nitro, C.sub.1 -C.sub.4 lower ester, C.sub.1 -C.sub.4 lower alkyl, C.sub.1 -C.sub.4 lower thioalkyl, substituted or unsubstituted C.sub.3 -C.sub.6 cycloalkyl, C.sub.1 -C.sub.4 lower alkoxy, C.sub.1 -C.sub.4 lower thioalkoxy, substituted or unsubstituted aryl, substituted or unsubstituted lower arylalkoxy, substituted or unsubstituted lower alkylamino, or lower alkyl substituted or unsubstituted carbamate; or among R.sub.3, R.sub.4, R.sub.5, R.sub.6 and R.sub.7, two adjacent groups are bonded with each other to form 1,2-phenylene or 2,3-naphthylene; X is oxygen, sulfur, or substituted or unsubstituted imino; Y is bonded at the 3-position or 4-position of the aromatic ring part wherein Y is oxygen or --NR.sub.8 -- (wherein, R.sub.8 is the same with the above-mentioned R.sub.3.); Z is hydroxy, C.sub.1 -C.sub.4 lower alkoxy, C.sub.1 -C.sub.4 lower thioalkoxy, substituted or unsubstituted aryloxy, C.sub.1 -C.sub.4 lower alkylamino, substituted or unsubstituted cycloamino containing 1-5 nitrogen atoms; A is nitrogen or --CH.dbd.; its pharmaceutically acceptable acid addition salts and process for the preparation thereof.

  本发明涉及一种具有强抗肿瘤活性的新化合物，其通式为(I)： 其中R.sub.1和R.sub.2分别独立地为氢、取代或未取代的C.sub.1-C.sub.8烷基、取代或未取代的C.sub.3-C.sub.6环烷基、取代或未取代的C.sub.2-C.sub.8不饱和烷基、酮、取代或未取代的芳基、取代或未取代的C.sub.1-C.sub.4烷氧基、取代或未取代的芳基羟基、取代或未取代的氨基、C.sub.1-C.sub.4较低酯基、C.sub.1-C.sub.4较低硫酯基、硫醇、取代或未取代的羧基、环氧基、取代或未取代的C.sub.1-C.sub.4较低硫代烷氧基；或者R.sub.1和R.sub.2融合形成C.sub.3-C.sub.4饱和或不饱和链；R.sub.3、R.sub.4、R.sub.5、R.sub.6和R.sub.7独立地为氢、卤素、羟基、硝基、C.sub.1-C.sub.4较低酯基、C.sub.1-C.sub.4较低烷基、C.sub.1-C.sub.4较低硫代烷基、取代或未取代的C.sub.3-C.sub.6环烷基、C.sub.1-C.sub.4较低烷氧基、C.sub.1-C.sub.4较低硫代烷氧基、取代或未取代的芳基、取代或未取代的较低芳基氧基、取代或未取代的较低烷基氨基，或较低烷基取代或未取代的碳酸酯基；或在R.sub.3、R.sub.4、R.sub.5、R.sub.6和R.sub.7中，两个相邻的基团彼此连接形成1,2-苯基或2,3-萘基；X为氧、硫或取代或未取代的亚胺基；Y连接在芳香环部分的3-位或4-位，其中Y为氧或--NR.sub.8--（其中，R.sub.8与上述的R.sub.3相同）；Z为羟基、C.sub.1-C.sub.4较低烷氧基、C.sub.1-C.sub.4较低硫代烷氧基、取代或未取代的芳氧基、C.sub.1-C.sub.4较低烷基氨基、含有1-5个氮原子的取代或未取代的环氨基；A为氮或--CH.dbd.；其药学上可接受的酸盐和其制备方法。
• Urea derivative useful as an anti-cancer agent and process for preparing same
  申请人：Chaconne Nsi Co., Ltd.

  公开号：US20020019389A1

  公开（公告）日：2002-02-14

  The present invention relates to a novel urea derivative represented by the following formula (I), which is useful as an anti-cancer agent: 1 its pharmaceutically acceptable acid addition salt or stereoisomer, in which X, Y, B and Het have the meaning as defined in the specification, and to a process for preparing the compound of formula (I) and an anti-cancer composition comprising the compound of formula (I) as an active ingredient.

  本发明涉及一种新颖的尿素衍生物，其化学式如下（I），可用作抗癌剂：其药学上可接受的酸盐或立体异构体，其中X、Y、B和Het的含义如规范中所定义，并且涉及制备化合物的公式（I）以及包含公式（I）化合物作为活性成分的抗癌组合物的方法。
• Antipruritics
  申请人：Yasui Kiyoshi

  公开号：US20050101590A1

  公开（公告）日：2005-05-12

  It is intended to provide antipruritics (drugs to control itching, antiitch agents and drugs to stop itching). It is found out that a compound having an agonistic activity to the cannabinoid receptor shows an antipruritics effect.

  这意味着它旨在提供止痒药（用于控制瘙痒的药物，抗瘙痒剂和止痒药）。研究发现，具有激动性作用的大麻素受体的化合物具有止痒效果。
• Pyridone derivatives having affinity for cannabinoid 2-type receptor
  申请人：——

  公开号：US20040082619A1

  公开（公告）日：2004-04-29

  It was found that the compound having a binding activity to the cannabinoid type 2 receptor represented by the formula (I): 1 wherein R 1 is a group represented by the formula: —Y 1 —Y 2 —Y 3 —R a wherein Y 1 is single bond or the like; Y 2 is —C(═O)—NH— or the like; Y 3 is optionally substituted aryl or the like; R 2 is hydrogen or the like; R 3 is alkyl or the like; R 4 is alkyl or the like; R 5 is optionally substituted alkyl or the like; or R 3 and R 4 taken together with the adjacent atom form cyclic group or the like.

  发现具有与cannabinoid 2型受体结合活性的化合物，其代表式为（I）：1其中R1是由式表示的基团：—Y1—Y2—Y3—Ra其中Y1是单键或类似物；Y2是—C(═O)—NH—或类似物；Y3是可选取代芳基或类似物；R2是氢或类似物；R3是烷基或类似物；R4是烷基或类似物；R5是可选取代烷基或类似物；或R3和R4与相邻原子结合形成环状基团或类似物。
• Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor
  申请人：Tada Yukio

  公开号：US20060052411A1

  公开（公告）日：2006-03-09

  It was found that the compound having a binding activity to the cannabinoid type 2 receptor represented by the formula (I): wherein R 1 is a group represented by the formula: —Y 1 —Y 2 —Y 3 —R a wherein Y 1 is single bond or the like; Y 2 is —C(═O)—NH— or the like; Y 3 is optionally substituted aryl or the like; R 2 is hydrogen or the like; R 3 is alkyl or the like; R 4 is alkyl or the like; R 5 is optionally substituted alkyl or the like; or R 3 and R 4 taken together with the adjacent atom form cyclic group or the like.

  被发现的化合物具有与cannabinoid type 2 受体结合活性，其化学式为(I)，其中R1是由公式表示的基团：—Y1—Y2—Y3—Ra，其中Y1是单键或类似物；Y2是—C(═O)—NH—或类似物；Y3是可选择取代的芳基或类似物；R2是氢或类似物；R3是烷基或类似物；R4是烷基或类似物；R5是可选择取代的烷基或类似物；或R3和R4与相邻原子一起形成环状基团或类似物。